By Dr. Shipra Gandhi Roswell Park Comprehensive Cancer Center Endocrine therapy is the mainstay of the management of hormone receptor (HR) positive breast cancer. Until now, fulvestrant remained the only selective
By Paolo Tarantino, MD Dana-Farber Cancer Institute/Harvard Medical School “Overall, a major shift in the way we treat breast cancer has occurred in 2022, with the demonstration that patients with tumors
More
In this blog article, Dr. Dan Milner, Chief Medical Officer of the American Society for Clinical Pathology, discusses his experience about his participation in the 2022 Summit on Cancer Health Disparities held
More